NextCure Inc. (2US)
XMUN 
Summary
2US Chart
NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma Transcript
NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma Transcript
Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 107.9% in NextCure (NXTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NextCure Inc. (2US) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has NextCure Inc. ever had a stock split?
NextCure Inc. Profile
| Biotechnology Industry | Healthcare Sector | Michael S. Richman CEO | XMUN Exchange | US65343E2072 ISIN |
| US Country | 43 Employees | - Last Dividend | 14 Jul 2025 Last Split | 9 May 2019 IPO Date |
Overview
NextCure, Inc. is a trailblazing clinical-stage biopharmaceutical entity committed to the innovation and development of new immunomedicines. Its focus is on addressing cancers and other immune-related diseases by rejuvenating normal immune functionality. Founded in 2015 and based in Beltsville, Maryland, NextCure has positioned itself at the forefront of immunomedicine research. Through a strategic license agreement with Yale University, the company leverages cutting-edge scientific discoveries to fuel its development pipeline. The cornerstone of NextCure's mission is to harness the power of the immune system to fight disease, aiming to offer groundbreaking treatments that can transform the lives of patients worldwide.
Products and Services
- NC410
- NC762
- NC525
- Other Discoveries and Research Programs
This innovative immunomedicine is designed to counteract immune suppression by targeting LAIR-1. By inhibiting the activity of LAIR-1, NC410 aims to lift the veil of immune suppression that some cancers use to evade detection, thereby restoring the body's natural defense mechanisms against tumors.
A monoclonal antibody, NC762, distinguishes itself by specifically binding to B7-H4, a protein prevalent across multiple types of tumors. The interaction between NC762 and B7-H4 is designed to initiate a targeted immune response against cancer cells, potentially offering a new pathway to cancer treatment by exploiting a less common target in the oncogenic process.
This monoclonal antibody directly targets LAIR-1, but with a unique mechanism aimed at the selective eradication of AML blast cells and leukemic stem cells. By focusing on these malignant cells while sparing normal blood and hematopoietic stem cells, NC525 represents a promising therapeutic strategy for combating acute myeloid leukemia (AML) with minimal impact on the body's healthy cells.
NextCure is not limited to its current portfolio of drug candidates; it actively engages in the preclinical evaluation of additional novel immunomodulatory molecules. By continuously expanding its discovery efforts, the company aims to uncover and harness breakthroughs in immune modulation for therapeutic purposes, securing its place at the cutting edge of immunomedicine research.
